Cohort | Simple | Complex | P value | |
---|---|---|---|---|
Baseline characteristics | ||||
N (%) | 49 (100) | 30 (61.2) | 19 (38.8) | |
Male | 28 (57.1) | 16 (53.3) | 12 (53.2) | 0.5 |
Age (years) - Median(IQR) | 7.7 (1.4–11) | 6.4 (1.4–10.9) | 8.2 (0.5–12.3) | 0.68 |
Indigenous | 5 (10.2) | 3 (10) | 2 (10.53) | 1 |
MRSA | 5 (10.2) | 4 (13.3) | 1 (5.3) | 0.64 |
Healthcare associated | 12 (24.5) | 6 (20) | 6 (31.6) | 0.36 |
Malignancy | 9 (18.4) | 2 (6.7) | 7 (36.8) | 0.02 |
Device related | 10 (20.4) | 5 (16.7) | 5 (26.3) | 0.48 |
Outcomes of interest – Median (IQR) | ||||
Max CRP (mg/L) | 61 (34–222) | 50 (22–75) | 216 (75–251) | < 0.001 |
Time to Max CRP (days) | 1 (0–2) | 0 (0–2) | 2 (1–3) | < 0.01 |
ID consult – n (%) | 32 (65.3) | 20 (66.7) | 12 (63.2) | 0.8 |
Length of stay (days) | 17 (8–32) | 10 (6–24) | 42 (16–50) | < 0.001 |
Number of antibiotics | 4 (3–5) | 3 (3–4) | 5 (3–6) | < 0.01 |
Duration of antibiotics | 36 (20–44) | 34 (16–39) | 43 (24–65) | 0.03 |